Dupilumab demonstrates long-term safety, efficacy among children with asthma

NASHVILLE, Tenn. — Children aged 6 to 11 years with uncontrolled, moderate to severe type 2 asthma experienced clinical improvements with dupilumab through a 2-year study period, according to a presentation at the CHEST Annual Meeting.
Treatment had an acceptable long-term safety profile as well, Leonard B. Bacharier, MD, Janie Robinson and John Moore Lee Chair in Pediatrics at Vanderbilt University Medical Center, and colleagues wrote.
“This was a planned follow-up of the VOYAGE study to better learn the long-term safety and efficacy of dupilumab in children 6 to 11 years of age

NASHVILLE, Tenn. — Children aged 6 to 11 years with uncontrolled, moderate to severe type 2 asthma experienced clinical improvements with dupilumab through a 2-year study period, according to a presentation at the CHEST Annual Meeting.
Treatment had an acceptable long-term safety profile as well, Leonard B. Bacharier, MD, Janie Robinson and John Moore Lee Chair in Pediatrics at Vanderbilt University Medical Center, and colleagues wrote.
“This was a planned follow-up of the VOYAGE study to better learn the long-term safety and efficacy of dupilumab in children 6 to 11 years of age